Ifinatamab Deruxtecan for Cancer

This trial tests a new cancer treatment called ifinatamab deruxtecan, designed for children whose solid tumors have returned or resisted previous treatments. The goal is to determine if this treatment can shrink or eliminate the cancer and whether young children can tolerate it safely. Suitable candidates are those under 12 years old with a solid tumor that has worsened after prior treatments and who lack other viable treatment options. As a Phase 1 and Phase 2 trial, the research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group of patients.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that ifinatamab deruxtecan, the treatment under study, is generally well-tolerated by patients. In studies involving individuals with small cell lung cancer, 36.5% of participants experienced serious side effects related to the treatment. Common side effects included nausea, low white blood cell levels (neutropenia), and low red blood cell levels (anemia). However, these side effects were considered manageable. Overall, the safety profile of ifinatamab deruxtecan resembles that of similar treatments, suggesting it is safe for many patients.¹²³⁴⁵

Ifinatamab Deruxtecan is unique because it combines an antibody with a chemotherapy drug, specifically targeting and attacking cancer cells. Unlike standard treatments like chemotherapy, which can affect both healthy and cancerous cells, Ifinatamab Deruxtecan is designed to precisely deliver its toxic payload to cancer cells, potentially reducing side effects. Researchers are excited about this treatment because its targeted approach could improve effectiveness and safety, offering new hope for patients with difficult-to-treat cancers.

Research has shown that ifinatamab deruxtecan (I-DXd) may effectively treat certain cancers. In a study with patients who had previously treated small cell lung cancer, I-DXd significantly shrank tumors in nearly half of the patients. The treatment also prevented cancer from worsening for an average of 4.9 months and extended patients' lives for an average of 10.3 months after starting treatment. These results suggest that I-DXd might also benefit other hard-to-treat cancers, such as relapsed or stubborn solid tumors in children. Participants in this trial will receive ifinatamab deruxtecan via intravenous (IV) infusion on day 1 of each 3-week cycle until discontinuation or progression.¹²⁵⁶⁷